Drug Trial Radar · NCT03292536
Merestinib on Bone Metastases in Subjects With Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jan 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Jan 11, 2018
Primary completion
Jun 24, 2019
Study completion Jun 24, 2019
Sponsor
- Lead sponsor
- University of UtahAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eli Lilly and Company
- First posted
- Sep 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.
Conditions
- Bone Metastases
- Breast Cancer
Interventions
MerestinibDrug
\*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\* Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events that OccurTime frame: 12 weeks, checked at every visit in that time period
- Change in urinary N-telopeptide levelTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huntsman Cancer Institute
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.